National and Kapodistrian University of Athens
Μελέτη οστικού μεταβολισμού στο πολλαπλούν μυέλωμα
Abstract
dc:descriptionMultiple myeloma (MM) is a malignancy of B-cells characterized by monoclonal development of plasma cells in the bone marrow. The main clinical feature is bone disease characterized by the presence of lytic lesions. The purpose of this study was to detect and measure the levels of cytokines and molecules involved in the pathogenesis of bone disease, correlate them with clinical data and explore their alterations when administering therapy. The measurement of the above molecules was made in the serum of patients with MM, using ELISA methodology. Patients with MM at diagnosis have both increased osteoclast activity and bone resorption, as reflected by increased levels of activation markers of osteoclasts (sRANKL, sRANKL/OPG, CCL-3, OPN) and bone resorption (CTX, NTX, TRACP-5b) and partly suppressed osteoblast function and bone formation, as reflected by the elevated values of inhibitors of osteoblasts (Dkk-1, activin-A, sclerostin) and the reduced levels of markers of bone synthesis (bALP and OC). The increased angiogenic cytokines (VEGF, VEGF-A, bFGF, angiogenin, angiopoetin-2) reflect the importance of angiogenesis in the pathogenesis of MM. The diffuse pattern of bone marrow infiltration on MRI is associated with increased angiogenesis, negative clinical features and is an independent predictor of lower survival even in patients treated with novel agents, suggesting the use of more aggressive therapy in these patients. The combination of thalidomide-dexamethasone (TD) in patients with refractory/relapsed MM suppresses osteoclasts and significantly reduces the sRANKL/OPG ratio and subsequently bone resorption markers with no effect on osteoblasts since there are no changes in markers of bone formation. The combination of lenalidomide-dexamethasone (RD) in patients with refractory/relapsed MM reduces osteoclast activity and bone resorption but only in patients who responded to treatment, with no positive effect on osteoblasts. The administration of bortezomib in patients with refractory/relapsed MM significantly reduces osteoblast inhibitors Dkk-1 and sclerostin, resulting in an increase in bone formation as reflected by the increase in serum osteocalcin and bALP.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2012
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Christoulas, Dimitrios
- Χριστούλας, Δημήτριος
Subjects
dc:subject × 20- Πολλαπλούν μυέλωμα
- Οστική νόσος
- Μαγνητική τομογραφία
- Αγγειογένεση
- Σκληροστίνη
- Ακτιβίνη Α
- Ανοσοτροποποιητικοί παράγοντες
- Βορτεζομίδη
- Multiple myeloma
- Bone disease
- MRI
- Angiogenesis
- Sclerostin
- Activin A
- IMiDs
- Bortezomid
- Ιατρική και Επιστήμες Υγείας
- Κλινική Ιατρική
- Medical and Health Sciences
- Clinical Medicine
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/29683